Pharmacokinetics and tissue distribution of pterostilbene in the rat

Molecular Nutrition and Food Research

Volumn 58, Issue 11, 2014, Pages 2122-2132

  Azzolini, Michele ^a   La Spina, Martina ^a,b   Mattarei, Andrea ^a,b   Paradisi, Cristina ^a   Zoratti, Mario ^a,b   Biasutto, Lucia ^a,b  

^a UNIVERSITY OF PADOVA   (Italy)

^b CNR   (Italy)

Author keywords

Area under the curve; LC; Pharmacokinetics; Pterostilbene; Tissue distribution

Indexed keywords

RATTUS;

PTEROSTILBENE; STILBENE DERIVATIVE;

ANIMAL; BIOAVAILABILITY; BLOOD; CALIBRATION; DOSE RESPONSE; DRUG EFFECTS; HALF LIFE TIME; HIGH PERFORMANCE LIQUID CHROMATOGRAPHY; INTRAVENOUS DRUG ADMINISTRATION; LIVER; MALE; METABOLISM; ORAL DRUG ADMINISTRATION; RAT; TISSUE DISTRIBUTION; WISTAR RAT;

ADMINISTRATION, INTRAVENOUS; ADMINISTRATION, ORAL; ANIMALS; BIOLOGICAL AVAILABILITY; CALIBRATION; CHROMATOGRAPHY, HIGH PRESSURE LIQUID; DOSE-RESPONSE RELATIONSHIP, DRUG; HALF-LIFE; LIVER; MALE; RATS; RATS, WISTAR; STILBENES; TISSUE DISTRIBUTION;

EID: 84907545089     PISSN: 16134125     EISSN: 16134133     Source Type: Journal    
DOI: 10.1002/mnfr.201400244     Document Type: Article

References (61)

1. McCormack, D., McFadden, D., A review of pterostilbene antioxidant activity and disease modification. Oxid. Med. Cell Longev. 2013, 2013, 575482.
2. Pterostilbene. Monograph. Altern. Med. Rev. 2010, 15, 159-163.
3. Estrela, J. M., Ortega, A., Mena, S., Rodriguez, M. L. et al., Pterostilbene: Biomedical applications. Crit. Rev. Clin. Lab. Sci. 2013, 50, 65-78.
4. Paul, S., DeCastro, A. J., Lee, H. J., Smolarek, A. K. et al., Dietary intake of pterostilbene, a constituent of blueberries, inhibits the beta-catenin/p65 downstream signaling pathway and colon carcinogenesis in rats. Carcinogenesis 2010, 31, 1272-1278.
5. Rimando, A. M., Kalt, W., Magee, J. B., Dewey, J. et al., Resveratrol, pterostilbene, and piceatannol in vaccinium berries. J. Agric. Food Chem. 2004, 52, 4713-4719.
6. Schmidlin, L., Poutaraud, A., Claudel, P., Mestre, P. et al., A stress-inducible resveratrol O-methyltransferase involved in the biosynthesis of pterostilbene in grapevine. Plant Physiol. 2008, 148, 1630-1639.
7. Paul, B., Masih, I., Deopujari, J., Charpentier, C., Occurrence of resveratrol and pterostilbene in age-old darakchasava, an ayurvedic medicine from India. J. Ethnopharmacol. 1999, 68, 71-76.
8. Paul, S., Rimando, A. M., Lee, H. J., Ji, Y. et al., Anti-inflammatory action of pterostilbene is mediated through the p38 mitogen-activated protein kinase pathway in colon cancer cells. Cancer Prev. Res. (Phila) 2009, 2, 650-657.
9. McCormack, D., McDonald, D., McFadden, D., Pterostilbene ameliorates tumor necrosis factor alpha-induced pancreatitis in vitro. J. Surg. Res. 2012, 178, 28-32.
10. Cichocki, M., Paluszczak, J., Szaefer, H., Piechowiak, A. et al., Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFkappaB, AP-1, COX-2, and iNOS in mouse epidermis. Mol. Nutr. Food Res. 2008, 52 (Suppl 1), S62-S70.
11. Tsai, M. L., Lai, C. S., Chang, Y. H., Chen, W. J. et al., Pterostilbene, a natural analogue of resveratrol, potently inhibits 7, 12-dimethylbenz[a]anthracene (DMBA)/12-O-tetradecanoylphorbol-13-acetate (TPA)-induced mouse skin carcinogenesis. Food Funct. 2012, 3, 1185-1194.
12. Chiou, Y. S., Tsai, M. L., Nagabhushanam, K., Wang, Y. J. et al., Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J. Agric. Food Chem. 2011, 59, 2725-2733.
13. Chang, J., Rimando, A., Pallas, M., Camins, A. et al., Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging 2012, 33, 2062-2071.
14. Suh, N., Paul, S., Hao, X., Simi, B. et al., Pterostilbene, an active constituent of blueberries, suppresses aberrant crypt foci formation in the azoxymethane-induced colon carcinogenesis model in rats. Clin. Cancer Res. 2007, 13, 350-355.
15. Li, K., Dias, S. J., Rimando, A. M., Dhar, S. et al., Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS One 2013, 8, e57542.
16. Kapoor, S., Pterostilbene and its emerging antineoplastic effects: a prospective treatment option for systemic malignancies. Am. J. Surg. 2013, 205, 483.
17. Mak, K. K., Wu, A. T., Lee, W. H., Chang, T. C. et al., Pterostilbene, a bioactive component of blueberries, suppresses the generation of breast cancer stem cells within tumor microenvironment and metastasis via modulating NF-kappaB/microRNA 448 circuit. Mol. Nutr. Food Res. 2013, 57, 1123-1134.
18. McCormack, D., McFadden, D., Pterostilbene and cancer: current review. J. Surg. Res. 2012, 173, e53-e61.
19. Mena, S., Rodriguez, M. L., Ponsoda, X., Estrela, J. M. et al., Pterostilbene-induced tumor cytotoxicity: a lysosomal membrane permeabilization-dependent mechanism. PLoS One 2012, 7, e44524.
20. Rimando, A. M., Nagmani, R., Feller, D. R., Yokoyama, W., Pterostilbene, a new agonist for the peroxisome proliferator-activated receptor alpha-isoform, lowers plasma lipoproteins and cholesterol in hypercholesterolemic hamsters. J. Agric. Food Chem. 2005, 53, 3403-3407.
21. Manickam, M., Ramanathan, M., Jahromi, M. A., Chansouria, J. P. et al., Antihyperglycemic activity of phenolics from Pterocarpus marsupium. J. Nat. Prod. 1997, 60, 609-610.
22. Pari, L., Satheesh, M. A., Effect of pterostilbene on hepatic key enzymes of glucose metabolism in streptozotocin- and nicotinamide-induced diabetic rats. Life Sci. 2006, 79, 641-645.
23. Joseph, J. A., Fisher, D. R., Cheng, V., Rimando, A. M. et al., Cellular and behavioral effects of stilbene resveratrol analogues: implications for reducing the deleterious effects of aging. J. Agric. Food Chem. 2008, 56, 10544-10551.
24. Cherniack, E. P., A berry thought-provoking idea: the potential role of plant polyphenols in the treatment of age-related cognitive disorders. Br. J. Nutr. 2012, 108, 794-800.
25. Ramkumar, K. M., Sekar, T. V., Foygel, K., Elango, B. et al., Reporter protein complementation imaging assay to screen and study Nrf2 activators in cells and living animals. Anal. Chem. 2013, 85, 7542-7549.
26. Kundu, J. K., Surh, Y. J., Nrf2-Keap1 signaling as a potential target for chemoprevention of inflammation-associated carcinogenesis. Pharm. Res. 2010, 27, 999-1013.
27. Copple, I. M., The Keap1-Nrf2 cell defense pathway-a promising therapeutic target? Adv. Pharmacol. 2012, 63, 43-79.
28. Chiou, Y. S., Tsai, M. L., Wang, Y. J., Cheng, A. C. et al., Pterostilbene inhibits colorectal aberrant crypt foci (ACF) and colon carcinogenesis via suppression of multiple signal transduction pathways in azoxymethane-treated mice. J. Agric. Food Chem. 2010, 58, 8833-8841.
29. Mikstacka, R., Przybylska, D., Rimando, A. M., Baer-Dubowska, W., Inhibition of human recombinant cytochromes P450 CYP1A1 and CYP1B1 by trans-resveratrol methyl ethers. Mol. Nutr. Food. Res. 2007, 51, 517-524.
30. Kapetanovic, I. M., Muzzio, M., Huang, Z., Thompson, T. N. et al., Pharmacokinetics, oral bioavailability, and metabolic profile of resveratrol and its dimethylether analog, pterostilbene, in rats. Cancer Chemother. Pharmacol. 2011, 68, 593-601.
31. Walle, T., Methylation of dietary flavones greatly improves their hepatic metabolic stability and intestinal absorption. Mol. Pharm. 2007, 4, 826-832.
32. Lin, H. S., Yue, B. D., Ho, P. C., Determination of pterostilbene in rat plasma by a simple HPLC-UV method and its application in pre-clinical pharmacokinetic study. Biomed. Chromatogr. 2009, 23, 1308-1315.
33. Yeo, S. C., Ho, P. C., Lin, H. S., Pharmacokinetics of pterostilbene in Sprague-Dawley rats: the impacts of aqueous solubility, fasting, dose escalation, and dosing route on bioavailability. Mol. Nutr. Food Res. 2013, 57, 1015-1025.
34. Remsberg, C. M., Yanez, J. A., Ohgami, Y., Vega-Villa, K. R. et al., Pharmacometrics of pterostilbene: preclinical pharmacokinetics and metabolism, anticancer, antiinflammatory, antioxidant and analgesic activity. Phytother. Res. 2008, 22, 169-179.
35. Neto, C. C., Cranberry and blueberry: evidence for protective effects against cancer and vascular diseases. Mol. Nutr. Food Res. 2007, 51, 652-664.
36. Riche, D. M., Deschamp, D., Griswold, M. E., McEwen, C. L. et al., Impact of pterostilbene on blood pressure and other metabolic parameters in adults. Hypertension 2012, 60, A617.
37. Riche, D. M., McEwen, C. L., Riche, K. D., Sherman, J. J. et al., Analysis of safety from a human clinical trial with pterostilbene. J. Toxicol. 2013, 2013, 463595.
38. Ruiz, M. J., Fernandez, M., Pico, Y., Manes, J. et al., Dietary administration of high doses of pterostilbene and quercetin to mice is not toxic. J. Agric. Food Chem. 2009, 57, 3180-3186.
39. Gottumukkala, V. S., Hindupur, R. M., Masna, M., Novel stilbene analogs. Patent WO 2010/046926 A2. 2010.
40. Iwuchukwu, O. F., Sharan, S., Canney, D. J., Nagar, S., Analytical method development for synthesized conjugated metabolites of trans-resveratrol, and application to pharmacokinetic studies. J. Pharm. Biomed. Anal. 2012, 63, 1-8.
41. Hoshino, J., Park, E. J., Kondratyuk, T. P., Marler, L. et al., Selective synthesis and biological evaluation of sulfate-conjugated resveratrol metabolites. J. Med. Chem. 2010, 53, 5033-5043.
42. Biasutto, L., Marotta, E., Garbisa, S., Zoratti, M. et al., Determination of quercetin and resveratrol in whole blood-implications for bioavailability studies. Molecules 2010, 15, 6570-6579.
43. Zhang, Y., Huo, M., Zhou, J., Xie, S., PKSolver: an add-in program for pharmacokinetic and pharmacodynamic data analysis in Microsoft Excel. Comput. Methods Programs Biomed. 2010, 99, 306-314.
44. Juan, M. E., Maijo, M., Planas, J. M., Quantification of trans-resveratrol and its metabolites in rat plasma and tissues by HPLC. J. Pharm. Biomed. Anal. 2010, 51, 391-398.
45. de Boer, V. C., Dihal, A. A., van der Woude, H., Arts, I. C. et al., Tissue distribution of quercetin in rats and pigs. J. Nutr. 2005, 135, 1718-1725.
46. Shao, X., Chen, X., Badmaev, V., Ho, C. T. et al., Structural identification of mouse urinary metabolites of pterostilbene using liquid chromatography/tandem mass spectrometry. Rapid Commun. Mass. Spectrom. 2010, 24, 1770-1778.
47. Dellinger, R. W., Garcia, A. M., Meyskens, F. L., Jr., Differences in the glucuronidation of resveratrol and pterostilbene: altered enzyme specificity and potential gender differences. Drug Metab. Pharmacokinet. 2014, 29, 112-119.
48. Bresciani, L., Calani, L., Bocchi, L., Delucchi, F. et al., Bioaccumulation of resveratrol metabolites in myocardial tissue is dose-time dependent and related to cardiac hemodynamics in diabetic rats. Nutr. Metab. Cardiovasc. Dis. 2014, 24, 408-415.
49. Menet, M. C., Marchal, J., Dal-Pan, A., Taghi, M. et al., Resveratrol metabolism in a non-human primate, the grey mouse lemur (Microcebus murinus), using ultra-high-performance liquid chromatography-quadrupole time of flight. PLoS One 2014, 9, e91932.
50. Hashimoto, H., Tokunaka, S., Sasaki, M., Nishihara, M. et al., Dimethylsulfoxide enhances the absorption of chemotherapeutic drug instilled into the bladder. Urol. Res. 1992, 20, 233-236.
51. Zhou, Y., Li, W., Chen, L., Ma, S. et al., Enhancement of intestinal absorption of akebia saponin D by borneol and probenecid in situ and in vitro. Environ. Toxicol. Pharmacol. 2010, 29, 229-234.
52. Calamini, B., Ratia, K., Malkowski, M. G., Cuendet, M. et al., Pleiotropic mechanisms facilitated by resveratrol and its metabolites. Biochem. J. 2010, 429, 273-282.
53. Menendez, C., Duenas, M., Galindo, P., Gonzalez-Manzano, S. et al., Vascular deconjugation of quercetin glucuronide: the flavonoid paradox revealed? Mol. Nutr. Food Res. 2011, 55, 1780-1790.
54. Terao, J., Murota, K., Kawai, Y., Conjugated quercetin glucuronides as bioactive metabolites and precursors of aglycone in vivo. Food Funct. 2011, 2, 11-17.
55. Abd El-Mohsen, M., Bayele, H., Kuhnle, G., Gibson, G. et al., Distribution of [3H]trans-resveratrol in rat tissues following oral administration. Br. J. Nutr. 2006, 96, 62-70.
56. Patel, K. R., Andreadi, C., Britton, R. G., Horner-Glister, E. et al., Sulfate metabolites provide an intracellular pool for resveratrol generation and induce autophagy with senescence. Sci. Transl. Med. 2013, 5, 205ra133.
57. Asensi, M., Medina, I., Ortega, A., Carretero, J. et al., Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 2002, 33, 387-398.
58. Liang, L., Liu, X., Wang, Q., Cheng, S. et al., Pharmacokinetics, tissue distribution and excretion study of resveratrol and its prodrug 3, 5, 4′-tri-O-acetylresveratrol in rats. Phytomedicine 2013, 20, 558-563.
59. Marier, J. F., Vachon, P., Gritsas, A., Zhang, J. et al., Metabolism and disposition of resveratrol in rats: extent of absorption, glucuronidation, and enterohepatic recirculation evidenced by a linked-rat model. J. Pharmacol. Exp. Ther. 2002, 302, 369-373.
60. Colom, H., Alfaras, I., Maijo, M., Juan, M. E. et al., Population pharmacokinetic modeling of trans-resveratrol and its glucuronide and sulfate conjugates after oral and intravenous administration in rats. Pharm. Res. 2011, 28, 1606-1621.
61. Das, S., Lin, H. S., Ho, P. C., Ng, K. Y., The impact of aqueous solubility and dose on the pharmacokinetic profiles of resveratrol. Pharm. Res. 2008, 25, 2593-2600.